Physician profile
Mark C Hartmann
NPI 1033385117
$9,164.30
in general payments reported to CMS, 2019-2025
42 companies · $2,842 in 2025
The $2,842 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,084 · 2022: $817 · 2023: $2,160 · 2024: $2,261 · 2025: $2,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,261 · Travel and Lodging: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,261.23 |
| Travel and Lodging | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $985.44 | 2021-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Abbvie INC. | $947.10 | 2021-2025 | |
| Amgen INC. | $527.97 | 2021-2025 | Evenity, Prolia, Repatha |
| Edwards Lifesciences Corporation | $499.95 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lilly USA, LLC | $484.57 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Regeneron Healthcare Solutions, INC. | $463.97 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $433.84 | 2024-2025 | Airsupra, Saphnelo, Wainua |
| Biohaven Pharmaceuticals, INC. | $390.55 | 2021 | |
| Novo Nordisk INC | $365.03 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $329.34 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $266.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $266.10 | 2023-2024 | Xarelto |
| Abbott Laboratories | $246.59 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $220.05 | 2025 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $196.51 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $170.72 | 2024-2025 | Impella |
| Biomerieux INC | $161.00 | 2025 | Filmarray |
| Exact Sciences Corporation | $158.22 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $154.34 | 2024 | Inspire |
| Boston Scientific Corporation | $149.08 | 2023 | Watchman Access System |
| Genentech, INC. | $148.92 | 2023 | Evrysdi |
| Si-Bone, INC. | $143.56 | 2023 | |
| Genentech USA, INC. | $130.74 | 2024 | Xolair |
| Janssen Biotech, INC. | $123.01 | 2023 | Simponi Aria |
| Neurocrine Biosciences, INC. | $122.95 | 2024 | Ingrezza |
| Ultragenyx Pharmaceutical INC. | $121.83 | 2023 | Crysvita |
| Idorsia Pharmaceuticals US INC | $118.31 | 2022 | |
| Ucb, INC. | $118.07 | 2024 | Bimzelx |
| Axsome Therapeutics, INC. | $109.69 | 2025 | Auvelity |
| Neurelis, INC. | $102.20 | 2024 | Valtoco |
| Sanofi-Aventis U.S. LLC | $87.43 | 2024-2025 | |
| Baxter Healthcare | $85.31 | 2023 | Floseal, Tisseel, Seprafilm |
| Astellas Pharma US INC | $55.22 | 2024 | Veozah |
| Acerus Pharmaceuticals Corporation | $47.38 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.51 | 2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $43.79 | 2021-2024 | Recombivax Hb, M-M-R II, Gardasil 9 |
| Almatica Pharma LLC | $29.99 | 2025 | Loreev Xr |
| Gilead Sciences, INC. | $25.29 | 2024 | |
| Antares Pharma, INC. | $25.14 | 2024 | Xyosted, Tlando |
| Eisai INC. | $22.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.88 | 2025 | |
| Phadia US INC. | $20.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hartmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.